Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United-Kingdom based holding company. It is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry, and medicinal chemistry. Its drug programs include Checkpoint Kinase 1 (Chk1), TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. The Checkpoint Kinase 1 (Chk1) inhibitor SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DNA damage response (DDR) network. The TYK2/JAK1 are both members of the Janus kinase (JAK) family of protein kinase enzymes with important roles in maintaining a healthy immune system. Both kinases promote inflammatory responses in autoimmune diseases, respiratory infections and tumor cell proliferation in certain cancers. Aurora+FLT3 Kinase Programme targets Acute Myeloid Leukemia (AML) and other blood cancers.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.81m
- Incorporated2004
- Employees6.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttp://www.sareum.co.uk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futura Medical plc. | 0.00 | -4.96m | 78.86m | 13.00 | -- | 8.11 | -- | -- | -0.018 | -0.018 | 0.00 | 0.0339 | 0.00 | -- | -- | -- | -73.87 | -65.78 | -93.73 | -86.83 | -- | -- | -- | -6,607.25 | -- | -- | -- | -- | -- | -- | -105.85 | -- | 123.78 | -- |
| Eco Animal Health Group Plc | 101.55m | 5.57m | 82.96m | 207.00 | 14.88 | 0.9923 | 5.85 | 0.8169 | 0.0823 | 0.0823 | 1.50 | 1.23 | 0.9131 | 2.17 | 3.60 | 490,584.50 | 11.31 | 10.55 | 15.40 | 13.14 | 49.93 | 48.53 | 12.38 | 14.62 | 2.57 | -- | 0.0145 | 47.19 | 46.46 | 17.51 | 109.45 | 6.21 | -30.72 | -29.40 |
| Science in Sport PLC | 62.54m | -6.82m | 83.45m | 218.00 | -- | 1.84 | -- | 1.33 | -0.0505 | -0.0505 | 0.4629 | 0.3262 | 0.9138 | 4.05 | 5.55 | 286,876.20 | -9.96 | -9.41 | -12.46 | -11.30 | 50.13 | 49.61 | -10.90 | -11.80 | 1.14 | -45.82 | 0.2197 | -- | 24.21 | 38.56 | -294.50 | -- | 46.77 | -- |
| e-Therapeutics plc | 477.00k | -8.07m | 100.21m | 32.00 | -- | 3.58 | -- | 210.09 | -0.0169 | -0.0169 | 0.001 | 0.0544 | 0.0217 | -- | 3.31 | 14,906.25 | -36.62 | -37.71 | -38.29 | -40.40 | 100.00 | 100.00 | -1,691.82 | -1,812.91 | -- | -- | 0.0239 | -- | 50.47 | -- | -119.06 | -- | 42.31 | -- |
| Scancell Holdings Plc | 0.00 | -8.41m | 100.88m | 25.00 | -- | 4.45 | -- | -- | -0.0105 | -0.0105 | 0.00 | 0.0278 | 0.00 | -- | -- | 0.00 | -21.98 | -48.49 | -24.78 | -52.14 | -- | -- | -- | -- | -- | -- | 0.2598 | -- | -- | -- | -181.09 | -- | -- | -- |
| Faron Pharmaceuticals Oy | 0.00 | -17.94m | 124.52m | 37.00 | -- | 50.44 | -- | -- | -0.3537 | -0.3537 | 0.00 | 0.0464 | 0.00 | -- | -- | 0.00 | -196.84 | -165.50 | -539.12 | -391.61 | -- | -- | -- | -487,178.90 | -- | -248.33 | 0.5486 | -- | -- | -- | -25.16 | -- | 38.80 | -- |
| Circassia Group PLC | 27.90m | 2.30m | 153.89m | 128.00 | 83.41 | 2.11 | 22.63 | 5.52 | 0.0044 | 0.0075 | 0.064 | 0.1742 | 0.2945 | 2.66 | 2.45 | 217,968.80 | 2.43 | -11.69 | 2.80 | -13.99 | 68.10 | 76.19 | 8.24 | -81.99 | 1.58 | -- | 0.0191 | -- | 16.74 | 3.85 | 108.58 | -- | -22.16 | -- |
| Sareum Holdings Plc | 0.00 | -1.81m | 156.56m | 6.00 | -- | 27.57 | -- | -- | -0.0273 | -0.0273 | 0.00 | 0.0834 | 0.00 | -- | -- | 0.00 | -48.39 | -49.67 | -51.44 | -54.40 | -- | -- | -- | -10,610.04 | -- | -- | 0.00 | -- | -100.00 | -- | -52.18 | -- | -- | -- |
| Redx Pharma PLC | 10.04m | -21.58m | 165.17m | 71.00 | -- | 12.58 | -- | 16.46 | -0.0855 | -0.0855 | 0.0391 | 0.0477 | 0.2769 | -- | 2.46 | 141,338.00 | -59.54 | -40.30 | -83.07 | -66.57 | -- | -- | -215.01 | -85.78 | -- | -11.63 | 0.5698 | -- | 76.52 | -- | -134.19 | -- | 11.17 | -- |
| Creo Medical Group PLC | 22.33m | -21.16m | 173.96m | 245.00 | -- | 2.96 | -- | 7.79 | -0.1346 | -0.1346 | 0.1419 | 0.3244 | 0.2782 | 3.12 | 5.08 | 102,891.70 | -26.37 | -- | -31.21 | -- | 45.54 | -- | -94.79 | -- | 2.17 | -53.68 | 0.1703 | -- | 69,899.11 | -- | -27.68 | -- | -- | -- |
| Animalcare Group Plc | 74.02m | -77.00k | 181.78m | 211.00 | -- | 2.31 | 21.84 | 2.46 | -0.0013 | -0.0013 | 1.23 | 1.31 | 0.6315 | 2.99 | 8.57 | 350,824.70 | -0.0657 | -- | -0.0768 | -- | 53.25 | -- | -0.104 | -- | 0.9664 | 7.16 | 0.1221 | -- | 5.01 | -- | -132.91 | -- | -- | -- |
| Bioventix PLC | 10.50m | 6.62m | 186.23m | 17.00 | 28.40 | 19.14 | 27.54 | 17.74 | 1.26 | 1.26 | 2.00 | 1.87 | 0.9615 | 2.51 | 2.78 | 617,437.10 | 60.65 | 52.37 | 65.69 | 55.55 | 92.83 | 92.30 | 63.08 | 65.29 | 10.60 | 123.63 | 0.00 | 70.90 | 5.98 | 14.65 | -6.54 | 14.01 | 65.43 | 27.46 |
Data as of May 20 2022. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
24.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Stockbrokers Ltd.as of 02 Jan 2022 | 7.54m | 11.08% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Jan 2022 | 4.09m | 6.01% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Jan 2022 | 2.93m | 4.30% |
| Jarvis Investment Management Ltd.as of 02 Jan 2022 | 744.34k | 1.09% |
| IG Markets Ltd.as of 02 Jan 2022 | 423.30k | 0.62% |
| HSBC Bank Plc (Market-Maker)as of 02 Jan 2022 | 403.66k | 0.59% |
| Tilney Investment Management Services Ltd.as of 02 Jan 2022 | 182.34k | 0.27% |
| Rowan Dartington & Co. Ltd. (Broker)as of 02 Jan 2022 | 170.20k | 0.25% |
| J. M. Finn & Co. Ltd.as of 02 Jan 2022 | 98.46k | 0.15% |
| KW Investment Management Ltd.as of 02 Jan 2022 | 95.80k | 0.14% |
More ▼
Data from 30 Sep 2020 - 05 May 2022Source: FactSet Research Systems Inc.
